Focus Stocks
Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2011 Financial Results
Published on Friday, 20 January 2012 09:01 Written by TradersHuddle Staff
NATICK, Mass., Jan. 20, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results for the fourth quarter and full year ended December 31, 2011 on Thursday, February 2, at 8:00 a.m. Eastern Time.
The call will be hosted by Hank Kucheman, Chief Executive Officer, Mike Mahoney, President, and Jeff Capello, Executive Vice President and Chief Financial Officer.
A live webcast of the conference call will be available via Boston Scientific's website. Webcast registration is available on the Investor Relations section of the website at www.bostonscientific.com/investors. Interested parties are encouraged to register at least 15 minutes prior to the scheduled start time to ensure a timely connection.
The webcast is also being distributed over Thomson Financial's Investor Distribution Network via two locations: www.earnings.com, which is accessible to the public, and www.streetevents.com, a password-protected event management site.
An archived replay of the webcast will be accessible at www.bostonscientific.com/investors approximately one hour following the completion of the conference call and available for approximately one year.
The Company will issue a press release announcing financial results for the fourth quarter and full year 2011 on Thursday, February 2, prior to the conference call.
About Boston Scientific
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
|
CONTACT: |
Denise Kaigler |
|
|
508-650-8330 (office) |
|
|
Media Relations |
|
|
Boston Scientific Corporation |
|
|
This e-mail address is being protected from spambots. You need JavaScript enabled to view it. |
|
|
|
|
|
Eric Olson |
|
|
336-293-4393 (office) |
|
|
Media Relations |
|
|
Boston Scientific Corporation |
|
|
This e-mail address is being protected from spambots. You need JavaScript enabled to view it. |
|
|
|
|
|
Sean Wirtjes |
|
|
508-652-5305 (office) |
|
|
Investor Relations |
|
|
Boston Scientific Corporation |
|
|
This e-mail address is being protected from spambots. You need JavaScript enabled to view it. |
SOURCE Boston Scientific Corporation
Related Articles
- Trading Idea: Entry Levels for Boston Scientific
- Bears Appeared on Boston Scientific
- Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
- PROMUS Element™ Stent Demonstrates Excellent Long-Term Safety and Effectiveness in PLATINUM Small Vessel Study
- Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent
- One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
- Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
- Boston Scientific Announces Schedule For EuroPCR 2012
- Boston Scientific Announces FDA Approval and First U.S. Implant of New Devices To Treat Bradycardia
- Boston Scientific Announces Schedule for Heart Rhythm Society Scientific Sessions
Related Partner Headlines
- Boston Scientific: PROMUS Element Stent Demonstrates Excellent Long-Term Safety and Effectiveness in PLATINUM Small Vessel Study - Benzinga
- Boston Scientific Announces FDA Approval and U.S. Launch of EPIC Vascular Stent - Benzinga
- Boston Scientific Announces Positive Data from Lotus Transcatheter Aortic Valve Trial - Benzinga
- Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial - Benzinga
- UPDATE: Citigroup Reiterates Neutral Rating, Raises PT for Boston Scientific - Benzinga
- Boston Scientific Announces Schedule For EuroPCR 2012 - Benzinga
- Boston Scientific Announces FDA Approval and First U.S. Implant of New Devices To Treat Bradycardia - Benzinga
- Boston Scientific Renews Agreement with Lumenis to Deliver Innovative Laser Products to Treat Urologic Conditions - Benzinga
- Boston Scientific Announces Launch of PROMUS Element Platinum Chromium Stent System in Japan - Benzinga
- Boston Scientific Announces First Implants of TELIGEN Implantable Defibrillator in China - Benzinga
TradersHuddle Search
| Sponsored By: |
|
Stock Search: |
|
Site Search: Loading
|
Latest Partner Headlines
-
Cramer's 'Mad Money' Recap: Put Some Meat Into Your Holdings With Hormel - TheStreet.com -
Market Preview: Feeling the Fear? - TheStreet.com -
Status Quo Is Good for Germany - TheStreet.com -
A Greek Exit Would Cut Both Ways - TheStreet.com -
Intel Corp (INTC): Today's Featured Electronics Loser - TheStreet.com -
Juniper Networks Inc. (JNPR): Today's Featured Technology Loser - TheStreet.com -
Celgene Corporation (CELG): Today's Featured Health Care Loser - TheStreet.com -
Safeway Inc. (SWY): Today's Featured Retail Loser - TheStreet.com
Stock Market
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,496.15 Trade time:4:05PM EDT Value change:▼6.66 (-0.05%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,318.86 Trade time:4:33PM EDT Value change:▲2.23 (0.17%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,850.12 Trade time:5:16PM EDT Value change:▲11.04 (0.39%)In The Wires
-
Sohu.com Announces Changyou.com Began Open Beta Testing of "Tao Yuan" on May 24, 2012 -
Changyou.com Began Open Beta Testing of "Tao Yuan" on May 24, 2012 -
Nation's Largest Golf Retailer Opens Two New Experiential Stores in Sterling and Fairfax -
Ford, Microsoft Tout Focus Electric Technologies as the Future of More Affordable, Efficient Transportation -
New Survey Of Mechanics Reveals Best Methods To Keep Cars Running Longer -
Navigating a New Course In Search – Introducing Yahoo! Axis -
Fundtech and HDFC Bank Win Asian Banker Award for Best Corporate Payments Implementation Project -
Mike The Pike Productions, Inc.’s Saint James Films Secures Worldwide Distribution Contract with Genre Powerhouse, TomCat Films, LLC









